Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
- 1 September 2004
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 37 (1) , 1147-1154
- https://doi.org/10.1097/01.qai.0000136738.24090.d0
Abstract
Although highly active antiretroviral therapy has been shown to lower plasma HIV-1 RNA in HIV infection, many patients do not reach the target goal of undetectable viremia. We evaluated whether risk of clinical progression varies by level of viral suppression achieved. Patients in the Collaborations in HIV Outcomes Research/United States cohort who maintained stable HIV-1 RNA levels of either 20,000 copies/mL during a run-in period of at least 6 months were studied. Baseline was the first day after this period. Proportional hazards models were used to quantify the relation between baseline HIV-1 RNA levels and risk of a new AIDS-defining diagnosis or death after adjusting for CD4 count, age, gender, ethnicity, study site, prior AIDS-defining diagnosis, and antiretroviral therapy history. Patients (N = 3010) were followed for up to 4.3 years after the 6-month run-in period, with 343 deaths or AIDS-defining diagnoses reported. The risk of a new AIDS-defining diagnosis or death was not significantly different in the 400 to 20,000– and 20,000-copies/mL group (26%, HR = 3.3, 95% CI: 2.5–4.4; P < 0.001 vs. the <400-copies/mL group). Median CD4 count changes during the first year of follow-up showed increases of 75 and 13 cells/mm3 for the 20,000-copies/mL group had a decrease of 23 cells/mm3. Patients who maintained baseline HIV-1 RNA levels of 400 to 20,000 copies/mL for at least 6 months preserved immunologic status and were no more likely to die or develop a new AIDS-defining diagnosis in the time frame studied than those with baseline levels 20,000 copies/mL at baseline had greater clinical and immunologic deterioration. These data suggest that maintenance of moderate viremia may confer clinical benefit not seen when viremia exceeds 20,000 copies/mL, and this should be taken into account when considering the risks and benefits of continuing failing therapy.Keywords
This publication has 43 references indexed in Scilit:
- Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus–Infected Patients with Very Low CD4 Cell CountsThe Journal of Infectious Diseases, 2002
- Association of Adherence toMycobacterium aviumComplex Prophylaxis and Antiretroviral Therapy with Clinical Outcomes in Acquired Immunodeficiency SyndromeClinical Infectious Diseases, 2002
- Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patientsAIDS, 2000
- Long‐Term Outcome and Treatment Modifications in a Prospective Cohort of Human Immunodeficiency Virus Type 1–Infected Patients on Triple‐Drug Antiretroviral RegimensClinical Infectious Diseases, 2000
- Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term StrategiesClinical Infectious Diseases, 2000
- Sustained CD4+T Cell Response after Virologic Failure of Protease Inhibitor–Based Regimens in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2000
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995